Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131477) titled 'A real-world study on perioperative treatment of liver cancer with camrelizumab combined with apatinib mesylate' on Sept. 2.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Affiliated Hospital of Qingdao University
Condition:
Study subjects: liver cancer patients with medium to high risk of recurrence who can undergo surgery
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-02
Target Sample Size: Group of camrelizumab combined with apatinib mesylate:2000;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/show...